Nitrogen-heterocyclic substituted 18β-glycyrrhetinic acid derivatives and their preparation and application
A technology of glycyrrhetinic acid and its derivatives, applied in the field of medicine, can solve the problems of poor water solubility, large gap in anticancer activity, and low bioavailability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0121] Example 1: Preparation of N-(2-iodo-3,11-dioxo-18β-oleanane-1,12-diene-30-acyl)-4-piperidinylpiperidine
[0122] Step A: Preparation of 3,11-dioxo-18β-oleanane-1,12-diene-30-carboxylic acid
[0123]
[0124] Weigh 3.5g (7.48mmol) GA and dissolve it in 150mL DMSO, add 8.37g (30mmol) IBX, and stir at reflux at 85°C for 4h. Cool to room temperature, pour 300mL 5% NaHCO 3 In solution, a white solid precipitated out. Extracted with ether (150mL×3), combined organic layers, washed with water, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated under reduced pressure to obtain 2.65g of white solid, yield: 76%. 1 H NMR (600MHz, DMSO-d 6 )δ12.21(1H,s),7.64(1H,d,J=10.2Hz),5.72(1H,d,J=10.8Hz),5.52(1H,s),2.73(1H,s),2.17~ 2.06(2H,m), 1.83~1.65(5H,m), 1.60~1.53(3H,m), 1.44~1.39(2H,m), 1.38(3H,s), 1.37~1.34(1H,m), 1.31(3H,s),1.29~1.25(1H,m),1.21~1.16(1H,m),1.11(3H,s),1.10(3H,s),1.07(3H,s),1.02(3H, s), 1.00~0.96(1H,m), 0.78(3H,s).
[0125]...
Embodiment 2
[0131] Example 2: Preparation of N-(2-iodo-3,11-dioxo-18β-oleanane-1,12-diene-30-acyl)-piperazine
[0132] According to the preparation method of Example 1, the raw material anhydrous piperazine was used instead of the raw material 4-piperidinylpiperidine in Example 1 to prepare the title compound. Mp: 150-153℃. IR(KBr): 3424.4, 2951.7, 2867.5, 1655.9, 1628.6, 1457.8, 1412.5, 1384.9, 1319.7, 1212.6, 1099.8, 1024.2, 975.8. 1 H NMR (600MHz, DMSO-d 6 )δ8.43(1H,s),5.61(1H,s),3.52~3.41(4H,m),2.87(1H,s),2.69~2.59(4H,m),2.31~2.23(1H,m) ,2.17~2.09(1H,m),1.99~1.93(1H,m),1.88~1.82(1H,m),1.82~1.61(4H,m),1.59~1.50(2H,m),1.46~1.39( 2H,m),1.38(3H,s),1.37~1.33(2H,m),1.32(3H,s),1.26~1.22(1H,m),1.20~1.17(1H,m),1.16(3H, s), 1.11(3H, s), 1.08(3H, s), 1.07(3H, s), 1.01~0.96(1H, m), 0.75(3H, s). 13 C NMR (150MHz, DMSO-d 6 )δ198.7, 197.8, 173.3, 172.7, 170.7, 127.4, 100.5, 60.2, 54.7, 51.5, 48.4, 46.4, 45.5, 45.4, 43.9, 43.8, 43.4, 40.5, 37.9, 32.5, 31.9, 31.5, 26.6, 2.8, 2 ,23.0,22.4,20.5,19...
Embodiment 3
[0133] Example 3: Preparation of N-(2-iodo-3,11-dioxo-18β-oleanane-1,12-diene-30-yl)-morpholine
[0134] According to the preparation method of Example 1, the raw material morpholine was used instead of the raw material 4-piperidinylpiperidine in Example 1 to prepare the title compound. Mp: 302-304℃. IR(KBr): 3424.2, 2959.8, 2872.7, 1681.3, 1648.1, 1631.9, 1385.7, 1268.6, 1210.7, 1173.5, 1117.3, 1024.4, 975.5. 1 H NMR (600MHz, DMSO-d 6 )δ8.43(1H,s),5.62(1H,s),3.62~3.48(8H,m),2.86(1H,s),2.30~2.24(1H,m),2.18~2.09(1H,m) ,1.99~1.93(1H,m),1.88~1.82(1H,m),1.82~1.63(4H,m),1.59~1.40(4H,m),1.38(3H,s),1.37~1.33(2H, m), 1.32(3H,s), 1.28~1.23(1H,m), 1.17(3H,s), 1.11(3H,s), 1.08(3H,s), 1.07(3H,s), 1.02~0.96 (1H,m),0.76(3H,s). 13 C NMR (150MHz, DMSO-d 6 )δ 198.8, 197.8, 173.7, 172.6, 170.7, 127.4, 100.5, 66.8, 54.8, 51.5, 48.4, 45.5, 45.4, 43.9, 43.8, 43.6, 43.4, 37.8, 32.3, 31.9, 31.5, 28.8, 28.8, 2 ,23.0,22.4,20.4,19.0,18.3. HRMS m / z calcd for C 34 h 49 INO 4 + [M+H] + 662.2701...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


